Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DoorDash, Inc. stock logo
DASH
DoorDash
$217.02
+0.4%		$186.14
$143.30
▼
$285.50
$94.03B1.784.15 million shs2.63 million shs
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$110.39
-0.3%		$108.10
$92.42
▼
$136.17
$36.82B0.263.48 million shs1.74 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$19.20
0.0%		$18.95
$14.02
▼
$21.84
$36.88B0.4720.22 million shs10.36 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$117.39
+2.6%		$105.16
$39.84
▼
$130.05
$9.76B1.95652,924 shs468,574 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DoorDash, Inc. stock logo
DASH
DoorDash
+0.35%+0.35%+14.12%+36.32%-14.63%
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
-0.28%+0.65%+3.62%+15.10%-18.11%
Kenvue Inc. stock logo
KVUE
Kenvue
-0.16%-0.14%+2.67%+12.34%-11.67%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+2.60%+9.18%+2.87%+42.79%+188.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DoorDash, Inc. stock logo
DASH
DoorDash
$217.02
+0.4%		$186.14
$143.30
▼
$285.50
$94.03B1.784.15 million shs2.63 million shs
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$110.39
-0.3%		$108.10
$92.42
▼
$136.17
$36.82B0.263.48 million shs1.74 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$19.20
0.0%		$18.95
$14.02
▼
$21.84
$36.88B0.4720.22 million shs10.36 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$117.39
+2.6%		$105.16
$39.84
▼
$130.05
$9.76B1.95652,924 shs468,574 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DoorDash, Inc. stock logo
DASH
DoorDash
+0.35%+0.35%+14.12%+36.32%-14.63%
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
-0.28%+0.65%+3.62%+15.10%-18.11%
Kenvue Inc. stock logo
KVUE
Kenvue
-0.16%-0.14%+2.67%+12.34%-11.67%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+2.60%+9.18%+2.87%+42.79%+188.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DoorDash, Inc. stock logo
DASH
DoorDash
2.67
Moderate Buy$254.0917.08% Upside
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
2.29
Hold$117.936.83% Upside
Kenvue Inc. stock logo
KVUE
Kenvue
2.20
Hold$19.270.40% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.83
Moderate Buy$125.657.04% Upside

Current Analyst Ratings Breakdown

Latest DASH, KVUE, KMB, and KYMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
Kenvue Inc. stock logo
KVUE
Kenvue
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$20.00 ➝ $19.00
8/10/2026
DoorDash, Inc. stock logo
DASH
DoorDash
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$200.00 ➝ $220.00
8/7/2026
DoorDash, Inc. stock logo
DASH
DoorDash
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
8/7/2026
DoorDash, Inc. stock logo
DASH
DoorDash
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$199.00 ➝ $225.00
8/7/2026
DoorDash, Inc. stock logo
DASH
DoorDash
Susquehanna logo
Susquehanna
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetPositive$225.00 ➝ $250.00
8/6/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$135.00
8/6/2026
DoorDash, Inc. stock logo
DASH
DoorDash
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$205.00 ➝ $220.00
8/6/2026
DoorDash, Inc. stock logo
DASH
DoorDash
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$330.00 ➝ $336.00
8/6/2026
DoorDash, Inc. stock logo
DASH
DoorDash
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$223.00 ➝ $225.00
8/6/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/6/2026
DoorDash, Inc. stock logo
DASH
DoorDash
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$250.00 ➝ $255.00
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DoorDash, Inc. stock logo
DASH
DoorDash
$15.89B5.92$4.06 per share53.39$22.90 per share9.48
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$16.58B2.21$9.95 per share11.09$5.63 per share19.61
Kenvue Inc. stock logo
KVUE
Kenvue
$15.12B2.44$1.38 per share13.92$5.49 per share3.50
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$105M92.96N/AN/A$18.15 per share6.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DoorDash, Inc. stock logo
DASH
DoorDash
$935M$1.91113.6249.66N/A5.29%8.48%4.37%N/A
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$2.02B$5.8818.7714.765.2711.79%143.92%14.21%10/29/2026 (Estimated)
Kenvue Inc. stock logo
KVUE
Kenvue
$1.47B$0.8722.0615.611.3710.76%21.22%8.37%11/2/2026 (Estimated)
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$311.35M-$3.24N/AN/AN/A-285.33%-21.22%-19.21%11/3/2026 (Estimated)

Latest DASH, KVUE, KMB, and KYMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Kenvue Inc. stock logo
KVUE
Kenvue
$0.3187$0.31-$0.0087$0.24$3.97 billion$3.96 billion
8/5/2026Q2 2026
DoorDash, Inc. stock logo
DASH
DoorDash
$0.4681$0.46-$0.0081$0.46$4.34 billion$4.45 billion
8/5/2026Q2 2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.7126-$0.62+$0.0926-$0.62$32.78 million$65.00 million
8/4/2026Q2 2026 Prepared Remarks
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$2.01$1.80-$0.21$1.04$4.22 billion$4.19 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DoorDash, Inc. stock logo
DASH
DoorDash
N/AN/AN/AN/AN/A
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
$5.124.64%+3.32%87.07%54 Years
Kenvue Inc. stock logo
KVUE
Kenvue
$0.844.38%N/A96.55%1 Years
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A

Latest DASH, KVUE, KMB, and KYMR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/3/2026
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
quarterly$1.284.76%9/4/20269/4/202610/2/2026
7/29/2026
Kenvue Inc. stock logo
KVUE
Kenvue
quarterly$0.214.43%8/12/20268/12/20268/26/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DoorDash, Inc. stock logo
DASH
DoorDash
0.27
1.37
1.37
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
3.45
0.91
0.69
Kenvue Inc. stock logo
KVUE
Kenvue
0.67
1.01
0.71
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
10.34
10.34

Institutional Ownership

CompanyInstitutional Ownership
DoorDash, Inc. stock logo
DASH
DoorDash
90.64%
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
76.29%
Kenvue Inc. stock logo
KVUE
Kenvue
97.64%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
DoorDash, Inc. stock logo
DASH
DoorDash
5.28%
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
0.75%
Kenvue Inc. stock logo
KVUE
Kenvue
1.59%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
15.98%
CompanyEmployeesShares OutstandingFree FloatOptionable
DoorDash, Inc. stock logo
DASH
DoorDash
31,400433.30 million412.71 millionOptionable
Kimberly-Clark Corporation stock logo
KMB
Kimberly-Clark
36,000332.58 million330.09 millionOptionable
Kenvue Inc. stock logo
KVUE
Kenvue
22,0001.92 billion1.89 billionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17083.15 million69.86 millionOptionable

Recent News About These Companies

Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
August 12 at 6:05 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/kymera-therapeutics-kymr-q2-2026-171404280.html
Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Still a Buy?
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/kymera-therapeutics-nasdaqkymr-sees-unusually-high-trading-volume-still-a-buy-2026-08-11/
HC Wainwright Issues Negative Estimate for KYMR Earnings
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951186
HC Wainwright Issues Negative Outlook for KYMR Earnings
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-negative-outlook-for-kymr-earnings-2026-08-10/
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (KRRO), Ardelyx (ARDX) and Kymera Therapeutics (KYMR)
August 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ARDX/pressreleases/3730887/analysts-have-conflicting-sentiments-on-these-healthcare-companies-korro-bio-krro-ardelyx-ardx-and-kymera-therapeutics-kymr/
Why Kymera Therapeutics (NASDAQ:KYMR) Is Drawing Fresh Attention This Week?
August 9, 2026  |  kalkinemedia.comK
KYMR Q3 EPS Estimate Lowered by Brookline Capital Markets
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949217
California State Teachers Retirement System Increases Stake in Kymera Therapeutics, Inc. $KYMR
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-increases-stake-in-kymera-therapeutics-inc-kymr-2026-08-08/
Q3 EPS Forecast for Kymera Therapeutics Cut by Analyst
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-eps-forecast-for-kymera-therapeutics-cut-by-analyst-2026-08-07/
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970366/kymr-q2-earnings-and-revenues-top-estimates-on-gilead-sanofi-payments?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2970366
Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR)
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/accelerated-kt-621-trial-narrower-071526806.html
Kymera Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931226-kymera-therapeutics-inc-2026-q2-results-earnings-call-presentation
Kymera targets year-end 2026 KT-621 AD data and maintains cash runway into 2029
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4626608-kymera-targets-year-end-2026-ktminus-621-ad-data-and-maintains-cash-runway-into-2029
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931150-kymera-therapeutics-inc-kymr-q2-2026-earnings-call-transcript
Kymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Beats Estimates By $0.09 EPS
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/kymera-therapeutics-nasdaqkymr-releases-earnings-results-beats-estimates-by-009-eps-2026-08-05/
Kymera Therapeutics Q2 Earnings Call Highlights
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/kymera-therapeutics-q2-earnings-call-highlights-2026-08-05/
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
August 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2968327/kymera-therapeutics-inc-kymr-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2968327
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339183/0/en/kymera-therapeutics-announces-second-quarter-2026-financial-results-and-provides-a-business-update.html
Earnings To Watch: Kymera Therapeutics Inc (KYMR) Q2 2026 -- GF Value Sees 80% Downside
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/earnings-watch-kymera-therapeutics-inc-132344124.html
The Manufacturers Life Insurance Company Cuts Holdings in Kymera Therapeutics, Inc. $KYMR
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-cuts-holdings-in-kymera-therapeutics-inc-kymr-2026-08-04/
Kymera Therapeutics, Inc. $KYMR Stock Holdings Trimmed by Dimensional Fund Advisors LP
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-kymera-therapeutics-inc-kymr-stock-holdings-trimmed-by-dimensional-fund-advisors-lp-2026-08-03/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
A DoorDash-branded delivery drone with a red and white cargo pod flies against a blue sky.
DoorDash's Drone Certification Could Reshape Its Delivery Margins
By Jeffrey Neal Johnson | July 30, 2026
A pepperoni pizza in an open Domino's box sits on a stainless steel prep table in a kitchen.
Is Domino's Stock Serving Up a Buying Opportunity?
By Jeffrey Neal Johnson | July 20, 2026
DoorDash stock logo

DoorDash NASDAQ:DASH

$217.02 +0.76 (+0.35%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$217.86 +0.84 (+0.39%)
As of 08/14/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DoorDash, Inc., together with its subsidiaries, operates a commerce platform that connects merchants, consumers, and independent contractors in the United States and internationally. The company operates DoorDash Marketplace and Wolt Marketplace, which provide various services, such as customer acquisition, demand generation, order fulfillment, merchandising, payment processing, and customer support. It also offers membership products, including DashPass and Wolt+; DoorDash Drive and Wolt Drive, which are white-label delivery fulfillment services that enable merchants that have generated consumer demand through their channels to fulfill demand using its platform; DoorDash Storefront that enables merchants to offer consumers on-demand access to e-commerce; and Bbot, which offers merchants digital ordering and payment solutions for in-store and online channels. In addition, the company enables merchants to advertise and promote on its platform to acquire consumers. The company was formerly known as Palo Alto Delivery Inc. and changed its name to DoorDash, Inc. in 2015. DoorDash, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Kimberly-Clark stock logo

Kimberly-Clark NASDAQ:KMB

$110.39 -0.31 (-0.28%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$110.20 -0.19 (-0.17%)
As of 08/14/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products in the United States. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The company's Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Poise, Depend, Plenitud, Softex, and other brand names. Its Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The company's K-C Professional segment offers wipers, tissues, towels, apparel, personal protective equipment, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. It also sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to distributors, manufacturing, lodging, office building, food service, and public facilities, as well as through e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Kenvue stock logo

Kenvue NYSE:KVUE

$19.20 -0.01 (-0.03%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$19.11 -0.08 (-0.42%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$117.39 +2.97 (+2.60%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$117.35 -0.04 (-0.04%)
As of 08/14/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas